Microbiomap®, the test that assesses endometrial microbiota and diagnoses chronic endometritis
IGLS has the MicroBioMap® test that checks the status of the endometrial microbiota and verifies the quality of the endometrial environment, making it easier for the practitioner to determine the appropriate treatment and thus maximizing the conditions for successful embryo implantation.
MicroBioMap® analyzes at the molecular level the presence of up to 18 pathogenic microorganisms, such as fungi, bacteria or protozoa, causative agents of what is known as Chronic Endometritis (CE). This condition consists of a persistent inflammation of the endometrial mucosa and affects around 190 million women of reproductive age worldwide, with a higher incidence in women with infertility problems.
In addition, not only is the presence of these pathogens analyzed, but this test detects, from the analysis of microbial DNA, 4 species of lactobacilli beneficial to the reproductive process, as well as their relative abundance.
Wy it is crucial to know the endometrial microbiota:
The endometrial microbiota is closely related to endometrial receptivity. Therefore, it is vital to detect those pathogenic agents capable of deteriorating the reproductive health of patients. Upon the arrival of the embryo, these agents can cause a significant increase in the risk of implantation failure, recurrent abortions, and other types of pathologies or problematic events during pregnancy.
On the other hand, quantifying the proportion of the 4 species of beneficial lactobacilli in the microbiota is a favourable indicator of the health status and receptivity of the endometrium.
How is the sample extracted?
There are different procedures depending on the type of therapy applied by each professional. In all of them, the microbiota analysis is carried out from an endometrial tissue biopsy, and the differences lie in the medication and the type of monitoring during the ovulatory cycle until obtaining said biopsy.
The patient maintains their cycle without alterations or added medication. By using various ovulation tests, the moment when luteinizing hormone (LH) undergoes a significant increase, approximately near the middle of the cycle, is identified. Seven days later, the tissue biopsy is performed.
Modified Natural Cycle:
It differs from the previous procedure in the induction of the increase of luteinizing hormone at the appropriate time of the cycle through the application of a slight dose of Human Chorionic Gonadotropin (hCG). The biopsy also takes place seven days after the application of the hCG and the consequent increase of LH.
Hormone Replacement Therapy Cycle (HRT):
During this process, the patient is given a daily dose of estrogen from the beginning of the cycle, while approximately in the middle of it, daily progesterone intake begins. The endometrial biopsy is obtained five and a half days after the start of progesterone intake.
Finally, once the endometrial biopsy is obtained, it is introduced into the MicroBioMap® Cryotube and stored for a minimum of 4 hours at a temperature of 4°C. Once refrigerated, the sample is sent at room temperature for genetic analysis. Results are obtained within 10 working days.